DOCSLIB.ORG

The Effect of Repeated Early Injury on Reward

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Effect of Repeated Early Injury on Reward The effect of repeated early injury on reward-related processing in the adult rat Lucie Alanna Low University College London 2010 Thesis presented for the degree of Doctor of Philosophy 1 Declaration: I, Lucie Low, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Lucie Low April 2010 2 Abstract Pain during early life can affect the developing central nervous system, leading to altered neural function in the adult organism. In this thesis, I investigate the long-term effects of repeated early pain on reward-related processing in the adult rat. I hypothesised that the reward system was likely to be sensitive to early activation of pain pathways, as the brain systems involved in both pain and reward overlap extensively, and virtually all centrally acting analgesic drugs are also drugs of reward. To begin, I investigate the extent to which the developing reward system is activated by a classic analgesic and drug of abuse, morphine. Comparing neonatal and adult activation of the dopaminergic system, results show that a single morphine challenge activates neonatal reward pathways, but that there are qualitative differences in the neonatal response to repeated morphine. Next, I show how reward-related behaviours of adult animals repeatedly injured as neonates differ from those of uninjured littermates, and finally propose the lateral hypothalamic orexin system as a biomarker reflecting this behaviour. The results provide evidence that neonatal injury interferes with the normal development of reward systems during a critical period of development, resulting in characteristic changes in reward behaviour and cell signalling in the adult animal. 3 Acknowledgements I firstly want to thank Maria for being such a fantastic supervisor. I’ve learnt such a huge amount from her guidance and wisdom, and am immensely grateful for her tutelage. I also want to thank Amanda Williams for being an excellent second supervisor, and for statistical help and advice. Plus thanks go to Steve Hunt, for his encyclopaedic knowledge, help and advice, and amusing sarcasm at times! Thanks to everyone in the Hunt/Fitzgerald lab for being such great colleagues over the past 4 years – special thanks to Gareth Hathway, Rebeccah Slater, Suellen Walker, David Vega-Avelaira, Stéphanie Koch, Keri Tochiki and Julia Slone-Murphy for help, ideas, support, friendship and many fun times. Thanks also to the Wellcome Trust and London Pain Consortium for funding me and enabling me to complete this research, and to Kate Jeffery and Brian Bye, plus all the people at the Institute of Behavioural Neuroscience, for their support and patience with my endless requests for ‘quiet on the corridor’. Finally, immense thanks go to my best mate Alex Kaye, and especially to my wonderful parents. I can’t thank them enough for their proof-reading skills, help and support over the last 27 years, and the course of this thesis – I really couldn’t have done it without you. X 4 1 INTRODUCTION .......................................................................................18 1.1 The problem of early pain......................................................................................................... 18 1.1.1 Pain management in neonates ................................................................................................. 19 1.1.2 Early pain in humans causes long-term alterations in pain circuitry and sensitivity............... 20 1.1.2.1 Effects are mediated by alterations in central nociceptive processing........................... 22 1.1.2.2 Prematurity can affect the stress response .....................................................................23 1.1.2.3 NICU experience can alter long-term cognitive development....................................... 23 1.1.3 Animal models provide information on the development of nociceptive processing ............. 24 1.1.3.1 Nociceptive transmission pathways............................................................................... 25 1.1.3.2 Spinal nociceptive processing develops over the first few weeks of an animal’s life ... 26 1.1.3.3 Descending inhibitory control from the brainstem is not mature in the neonatal rat..... 28 1.1.3.4 Long-term effects of neonatal noxious stimuli in rodents .............................................28 1.1.3.5 Critical periods in development and long-term effects.................................................. 30 1.2 Pain and reward processing are linked....................................................................................31 1.2.1 Areas of the brain involved in pain and reward processing overlap........................................31 1.2.1.1 NAcc.............................................................................................................................. 32 1.2.1.2 Amygdala ...................................................................................................................... 32 1.2.1.3 Anterior cingulate cortex............................................................................................... 32 1.2.2 Analgesia and relief from pain are rewarding.........................................................................33 1.2.2.1 Termination of a pain stimulus is rewarding .................................................................33 1.2.2.2 The placebo effect relies on reward processing.............................................................34 1.2.2.3 Rewarding stimuli induce analgesia .............................................................................. 34 1.2.2.4 Chronic pain states reduce reward responses.................................................................35 1.2.3 Endogenous opioids modulate pain and reward......................................................................35 1.2.4 Motivation-decision model ..................................................................................................... 36 1.2.5 Does early pain lead to altered reward processing in later life?.............................................. 38 1.3 The aims of this thesis................................................................................................................ 39 2 CHAPTER 2 – INVESTIGATING THE EFFECT OF MORPHINE ON NEONATAL REWARD PATHWAYS ...............................................................41 2.1 Introduction................................................................................................................................ 41 2.1.1 Dopamine (DA)....................................................................................................................... 41 2.1.1.1 Dopamine in the brain ................................................................................................... 42 2.1.2 Mesolimbic dopaminergic system........................................................................................... 44 2.1.2.1 Genetic manipulation of the DA system........................................................................45 2.1.3 Ventral Tegmental Area.......................................................................................................... 45 2.1.3.1 Firing properties of VTA DA cells................................................................................46 5 2.1.3.2 Behavioural studies........................................................................................................ 47 2.1.3.3 Human imaging studies ................................................................................................. 47 2.1.4 Ontogeny of the dopaminergic system.................................................................................... 48 2.1.4.1 Cell differentiation......................................................................................................... 48 2.1.4.2 Monoamine levels and receptor expression................................................................... 48 2.1.5 Opioids.................................................................................................................................... 49 2.1.5.1 Morphine ....................................................................................................................... 50 2.1.5.2 The developmental regulation of MOR expression and morphine function.................. 51 2.1.5.2.1 Ontogeny of MOR expression .................................................................................. 51 2.1.5.2.2 Binding to opioid receptors is seen prenatally .......................................................... 51 2.1.5.2.3 Morphine analgesia in the neonate............................................................................ 52 2.1.5.2.4 Chronic morphine administration in the neonate alters opioid signalling................. 52 2.1.5.2.5 Modulation of opioid signalling by external influences............................................ 53 2.1.5.3 Morphine is rewarding................................................................................................... 53 2.1.5.4 Morphine and dopaminergic signalling ......................................................................... 54 2.1.6 Reward processing in the neonate – the role of dopamine......................................................55 2.1.6.1 Bonding behaviour is mediated by dopaminergic pathways..........................................55 2.1.7 Morphine is rewarding in the neonate.....................................................................................56
Load more

Recommended publications
  • Neuroendocrine and Sympathetic Responses to an Orexin Receptor Antagonist, SB-649868, and Alprazolam Following Insulin-Induced Hypoglycemia in Humans
    Psychopharmacology (2014) 231:3817–3828 DOI 10.1007/s00213-014-3520-7 ORIGINAL INVESTIGATION Neuroendocrine and sympathetic responses to an orexin receptor antagonist, SB-649868, and Alprazolam following insulin-induced hypoglycemia in humans Ameera X. Patel & Sam R. Miller & Pradeep J. Nathan & Ponmani Kanakaraj & Antonella Napolitano & Philip Lawrence & Annelize Koch & Edward T. Bullmore Received: 8 October 2013 /Accepted: 24 February 2014 /Published online: 26 April 2014 # The Author(s) 2014. This article is published with open access at Springerlink.com Abstract it has previously been validated using the insulin tolerance test Rationale The orexin-hypocretin system is important for (ITT) model in humans. translating peripheral metabolic signals and central neuronal Results Of the primary endpoints, ITT induced defined in- inputs to a diverse range of behaviors, from feeding, motiva- creases in pulse rate, plasma cortisol, and adrenocorticotropic tion and arousal, to sleep and wakefulness. Orexin signaling is hormone in the placebo condition, but these responses were thus an exciting potential therapeutic target for disorders of not significantly impacted by alprazolam or SB-649868 pre- sleep, feeding, addiction, and stress. treatment. Of the secondary endpoints, ITT induced a defined Objectives/methods Here, we investigated the low dose phar- increase in plasma concentrations of adrenaline, noradrena- macology of orexin receptor antagonist, SB-649868, on neu- line, growth hormone (GH), and prolactin in the placebo roendocrine, sympathetic nervous system, and behavioral re- condition. Alprazolam pre-treatment significantly reduced sponses to insulin-induced hypoglycemic stress, in 24 healthy the GH response to ITT (p<0.003), the peak electromyogra- male subjects (aged 18–45 years; BMI 19.0–25.9 kg/m2), phy (p<0.0001) and galvanic skin response (GSR, p=0.04)to using a randomized, double-blind, placebo-controlled, acoustic startle, the resting GSR (p=0.01), and increased within-subject crossover design.
    [Show full text]
  • Orexin Receptor Antagonists As Therapeutic Agents for Insomnia
    REVIEW ARTICLE published: 25 December 2013 doi: 10.3389/fphar.2013.00163 Orexin receptor antagonists as therapeutic agents for insomnia Ana C. Equihua 1, Alberto K. De La Herrán-Arita 2 and Rene Drucker-Colin 1* 1 Neuropatología Molecular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City, México 2 Center for Sleep Sciences and Medicine, Stanford University, Palo Alto, CA, USA Edited by: Insomnia is a common clinical condition characterized by difficulty initiating or maintaining Christopher J. Winrow, Merck, USA sleep, or non-restorative sleep with impairment of daytime functioning. Currently, Reviewed by: treatment for insomnia involves a combination of cognitive behavioral therapy (CBTi) Matthew R. Ebben, Weill Medical and pharmacological therapy. Among pharmacological interventions, the most evidence College of Cornell University, USA Gabriella Gobbi, McGill University, exists for benzodiazepine (BZD) receptor agonist drugs (GABAA receptor), although Canada concerns persist regarding their safety and their limited efficacy. The use of these Matt Carter, University of hypnotic medications must be carefully monitored for adverse effects. Orexin (hypocretin) Washington, USA neuropeptides have been shown to regulate transitions between wakefulness and Michihiro Mieda, Kanazawa University, Japan sleep by promoting cholinergic/monoaminergic neural pathways. This has led to the *Correspondence: development of a new class of pharmacological agents that antagonize the physiological Rene Drucker-Colin, Departamento effects of orexin. The development of these agents may lead to novel therapies for de Neurociencias, Instituto de insomnia without the side effect profile of hypnotics (e.g., impaired cognition, disturbed Fisiología Celular, Universidad arousal, and motor balance difficulties). However, antagonizing a system that regulates Nacional Autónoma de México, Circuito exterior S/N, Apdo.
    [Show full text]
  • Hemispheric Differences in the Mesostriatal Dopaminergic System
    REVIEW ARTICLE published: 11 June 2014 SYSTEMS NEUROSCIENCE doi: 10.3389/fnsys.2014.00110 Hemispheric differences in the mesostriatal dopaminergic system Ilana Molochnikov and Dana Cohen* The Leslie and Susan Gonda Multidisciplinary Brain Research Center, Bar-Ilan University, Ramat-Gan, Israel Edited by: The mesostriatal dopaminergic system, which comprises the mesolimbic and the Ahmed A. Moustafa, University of nigrostriatal pathways, plays a major role in neural processing underlying motor and limbic Western Sydney, Australia functions. Multiple reports suggest that these processes are influenced by hemispheric Reviewed by: differences in striatal dopamine (DA) levels, DA turnover and its receptor activity. Here, Rachel Tomer, University of Haifa, Israel we review studies which measured the concentration of DA and its metabolites to Reuben Ruby Shamir, Case Western examine the relationship between DA imbalance and animal behavior under different Reserve University, USA conditions. Specifically, we assess evidence in support of endogenous, inter-hemispheric *Correspondence: DA imbalance; determine whether the known anatomy provides a suitable substrate for Dana Cohen, The Gonda Brain this imbalance; examine the relationship between DA imbalance and animal behavior; and Research Center, Bar Ilan University, Building number 901, Ramat Gan characterize the symmetry of the observed inter-hemispheric laterality in the nigrostriatal 52900, Israel and the mesolimbic DA systems. We conclude that many studies provide supporting e-mail: [email protected] evidence for the occurrence of experience-dependent endogenous DA imbalance which is controlled by a dedicated regulatory/compensatory mechanism. Additionally, it seems that the link between DA imbalance and animal behavior is better characterized in the nigrostriatal than in the mesolimbic system.
    [Show full text]
  • OREXIN ANTAGONISTS BELSOMRA (Suvorexant), DAYVIGO (Lemborexant)
    OREXIN ANTAGONISTS BELSOMRA (suvorexant), DAYVIGO (lemborexant) RATIONALE FOR INCLUSION IN PA PROGRAM Background Belsomra (suvorexant) and Dayvigo (lemborexant) are orexin receptor antagonists used to treat difficulty in falling and staying asleep (insomnia). Orexins are chemicals that are involved in regulating the sleep-wake cycle and play a role in keeping people awake (1-2). Regulatory Status FDA-approved indication: Orexin receptor antagonists are indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance (1-2). Orexin Antagonists are contraindicated in patients with narcolepsy (1-2). Orexin Antagonists are central nervous system (CNS) depressants that can impair daytime wakefulness even when used as prescribed. Medications that treat insomnia can cause next-day drowsiness and impair driving and other activities that require alertness. Orexin Antagonists can impair driving skills and may increase the risk of falling asleep while driving. People can be impaired even when they feel fully awake. Patients should also be made aware of the potential for next-day driving impairment, because there is individual variation in sensitivity to the drug (1-2). The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or mental illness that should be evaluated (1-2). Warnings and precautions that should be discussed with the patient on Orexin Antagonist therapy include adverse reactions on abnormal thinking and behavioral changes (such as amnesia, anxiety, hallucinations and other neuropsychiatric symptoms), complex behaviors (such as sleep- driving, preparing and eating food, or making phone calls), dose-dependent increase in suicidal ideation, and sleep paralysis which is the inability to move or speak for up to several minutes during sleep-wake transitions (1-2).
    [Show full text]
  • Ep 2330124 A2
    (19) TZZ ¥¥Z_ T (11) EP 2 330 124 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.06.2011 Bulletin 2011/23 C07K 14/575 (2006.01) (21) Application number: 10012149.0 (22) Date of filing: 11.08.2006 (84) Designated Contracting States: • Lewis, Diana AT BE BG CH CY CZ DE DK EE ES FI FR GB GR San Diego, CA 92121 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Soares, Christopher J. SK TR San Diego, CA 92121 (US) • Ghosh, Soumitra S. (30) Priority: 11.08.2005 US 201664 San Diego, CA 92121 (US) 17.08.2005 US 206903 • D’Souza, Lawrence 12.12.2005 US 301744 San Diego, CA 92121 (US) • Parkes, David G. (62) Document number(s) of the earlier application(s) in San Diego, CA 92121 (US) accordance with Art. 76 EPC: • Mack, Christine M. 06801467.9 / 1 922 336 San Diego, CA 92121 (US) • Forood, Behrouz Bruce (71) Applicant: Amylin Pharmaceuticals Inc. San Diego, CA 92121 (US) San Diego, CA 92121 (US) (74) Representative: Gowshall, Jonathan Vallance et al (72) Inventors: Forrester & Boehmert • Levy, Odile Esther Pettenkoferstrasse 20-22 San Diego, CA 92121 (US) 80336 München (DE) • Hanley, Michael R. San Diego, CA 92121 (US) Remarks: • Jodka, Carolyn M. This application was filed on 30-09-2010 as a San Diego, CA 92121 (US) divisional application to the application mentioned under INID code 62. (54) Hybrid polypeptides with selectable properties (57) The present invention relates generally to novel, tions and disorders include, but are not limited to, hyper- selectable hybrid polypeptides useful as agents for the tension, dyslipidemia, cardiovascular disease, eating treatment and prevention of metabolic diseases and dis- disorders, insulin-resistance, obesity, and diabetes mel- orders which can be alleviated by control plasma glucose litus of any kind, including type 1, type 2, and gestational levels, insulin levels, and/or insulin secretion, such as diabetes.
    [Show full text]
  • The Human Nervous System S Tructure and Function
    The Human Nervous System S tructure and Function S ixth Ed ition The Human Nervous System Structure and Function S ixth Edition Charles R. Noback, PhD Professor Emeritus Department of Anatomy and Cell Biology College of Physicians and Surgeons Columbia University, New York, NY Norman L. Strominger, PhD Professor Center for Neuropharmacology and Neuroscience Department of Surgery (Otolaryngology) The Albany Medical College Adjunct Professor, Division of Biomedical Science University at Albany Institute for Health and the Environment Albany, NY Robert J. Demarest Director Emeritus Department of Medical Illustration College of Physicians and Surgeons Columbia University, New York, NY David A. Ruggiero, MA, MPhil, PhD Professor Departments of Psychiatry and Anatomy and Cell Biology Columbia University College of Physicians and Surgeons New York, NY © 2005 Humana Press Inc. 999 Riverview Drive, Suite 208 Totowa, New Jersey 07512 www.humanapress.com All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise without written permission from the Publisher. All papers, comments, opinions, conclusions, or recommendations are those of the author(s), and do not necessarily reflect the views of the publisher. This publication is printed on acid-free paper. h ANSI Z39.48-1984 (American Standards Institute) Permanence of Paper for Printed Library Materials. Production Editor: Tracy Catanese Cover design by Patricia F. Cleary Cover Illustration: The cover illustration, by Robert J. Demarest, highlights synapses, synaptic activity, and synaptic-derived proteins, which are critical elements in enabling the nervous system to perform its role.
    [Show full text]
  • Drug Information Center Highlights of FDA Activities – 12/1/19 – 12/31/19
    Drug Information Center Highlights of FDA Activities – 12/1/19 – 12/31/19 FDA Drug Safety Communications & Drug Information Updates: Ranitidine and Nizatidine Updates: Detection of N‐nitrosodimethylamine (NDMA) 12/4/19 The FDA maintains a site with updates and press announcements on NDMA testing in ranitidine products and ranitidine recalls. They are requiring manufacturers test all lots of ranitidine and nizatidine prior to release. FDA Launches CURE ID App for Health Care Professionals 12/5/19 The FDA launched an internet repository for health care professionals to report their experience treating difficult‐ to‐treat infectious diseases with novel uses of existing FDA‐approved drugs. The CURE ID repository, accessible through a website, a smartphone or other medical device, is designed to enable crowdsourcing of medical information that may guide use of life‐saving interventions and facilitate development of new drugs. The application may be accessed at https://cure.ncats.io or by downloading “CURE ID” from the App or Play Store. NDMA Impurities Found in Metformin Outside the U.S.: Drug Information Update 12/6/19 The FDA is aware that low levels of NDMA have been detected in some metformin products available in other countries. The levels reported have been within the range naturally occurring in some foods and water. Currently no metformin product has been recalled in the U.S.; the FDA is working with manufacturers to test samples and will recall products if the levels are found to contain NDMA at levels above the acceptable daily intake limit of 96 ng. Public Safety Alert Due to Marketing of Unapproved Exosome Products 12/6/19 The FDA notified patients and healthcare practitioners of serious adverse effects experienced by patients who were treated with unapproved products marketed as containing exosomes, and issued a reminder that there are currently no FDA‐approved exosome products and any such use should be through a clinical trial with a product with an Investigational New Drug Application.
    [Show full text]
  • Orexin and Psychoneurobiology: a Hidden Treasure Hayder M
    Chapter Orexin and Psychoneurobiology: A Hidden Treasure Hayder M. Alkuraishy, Ali I. Al-Gareeb and Naseer A. Al-Harchan Abstract Orexin is a neuropeptide secreted from the lateral hypothalamus and prefrontal cortex concerned in wakefulness and excitement. This study aimed to review the pos- sible neurobiological effect of orexin. A diversity of search strategies was adopted and assumed which included electronic database searches of Medline and PubMed using MeSH terms, keywords, and title words. Orexin plays a vital role in activation of learn- ing, memory acquisition, and consolidation through activation of the monoaminergic system, which affects cognitive flexibility and cognitive function. Orexin stimulates adrenocorticotrophin (ACTH) and corticosteroid secretions via activation of the cen- tral corticotropin-releasing hormone (CRH). Cerebrospinal (CSF) and serum orexin serum levels are reduced in depression, schizophrenia, and narcolepsy. However, high orexin serum levels are revealed in drug addictions. Regarding neurodegenerative brain diseases, CSF and serum orexin levels are reduced in Parkinson’s disease (PD), Alzheimer’s disease (AD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Orexin antagonist leads to significant reduction of sympathetic overactivity during withdrawal syndrome. Also, orexin antagonist improves sleep pattern. The orexinergic system is involved in different psychiatric and neurological disorders; therefore targeting of this system could be a possible novel pathway in the management of these disorders. In addition measurement of CSF and serum orexin levels might predict the relapse and withdrawal of addict patients. Keywords: orexin, sleep disorders, psychiatric disorders, neurodegenerative disorders 1. Introduction Orexin, also known as hypocretin, is a neuropeptide that regulates arousal, wakefulness, and appetite.
    [Show full text]
  • Belsomra®: a Novel Dual Orexin Receptor Antagonist for the Treatment of Insomnia
    Pharmacy and Wellness Review Volume 7 Issue 1 Article 1 January 2016 Belsomra®: A Novel Dual Orexin Receptor Antagonist for the Treatment of Insomnia Shane Bogusz Ohio Northern University Steven Blake Ohio Northern University Michaela Wolford Ohio Northern University Victoria Cho Ohio Northern University Manoranjan D'Souza Ohio Northern University, [email protected] Follow this and additional works at: https://digitalcommons.onu.edu/paw_review Part of the Medical Pharmacology Commons, Nervous System Diseases Commons, Neurology Commons, and the Pharmaceutics and Drug Design Commons This Article is brought to you for free and open access by the ONU Journals and Publications at DigitalCommons@ONU. It has been accepted for inclusion in Pharmacy and Wellness Review by an authorized editor of DigitalCommons@ONU. For more information, please contact [email protected]. CNS Belsomra®: A Novel Dual Orexin Receptor Antagonist for the Treatment of Insomnia Shane Bogusz, Steven Blake, Michaela Wolford, Victoria Cho, Manoranjan D'Souza, M.D., Ph.D. Key Terms This knowledge-based activity is targeted for all pharmacists Belsomra®; Benzodiazepine; Dual Orexin Receptor Antago­ and is acceptable for 1.0 hour (0.1 CEU) of continuing nist; DORA, Insomnia, Insomnia Treatment, Orexin, education credit. This course requires completion Suvorexant of the program evaluation and at least a 70 percent grade on the program assessment questions. Introduction Insomnia refers to a disease state that involves persistent ACPE Universal Activity Number (UAN): 0048-0000-16-005-HOl-P difficulty falling asleep and/or frequent awakenings during sleep. Over 35 percent of the adult population exhibits one or To complete the continuing education program and receive more symptoms associated with insomnia, with 12 percent credit, please go to www.raabecollegeofpharmacy.org/PAW/.
    [Show full text]
  • Lemborexant for Insomnia
    Out of the Pipeline Lemborexant for insomnia David N. Neubauer, MD emborexant, FDA-approved for the Table 1 New agent treatment of insomnia, has demon- Fast facts about lemborexant promotes sleep strated efficacy in improving both sleep by suppressing L 1 Brand name: Dayvigo onset and sleep maintenance. This novel the wake drive compound is now the second approved Class: Dual orexin receptor antagonist supported by the insomnia medication classed as a dual orexin Indication: Insomnia characterized by difficulties with sleep onset and/or sleep orexin system receptor antagonist (Table 1). This targeted maintenance mechanism of action aims to enhance sleep Approval date: December 20, 2019 while limiting the adverse effects associated Availability date: June 2020 with traditional hypnotics. Manufacturer: Eisai Inc., Woodcliff Lake, New Jersey Clinical implications Dosage forms: 5-mg and 10-mg tablets Insomnia symptoms affect approximately Recommended dosage: 5 mg taken one-third of the general population at least immediately before going to bed with at least occasionally. Approximately 10% of indi- 7 hours remaining before the planned time viduals meet DSM-5 criteria for insomnia of awakening, no more than once per night. The dosage may be increased to 10 mg taken disorder, which require nighttime sleep once per night based on clinical response and difficulty and daytime consequences tolerance persisting for a minimum of 3 months.2 The prevalence is considerably higher in patients with chronic medical disorders and comorbid psychiatric conditions, especially similar mechanisms of action. There is 1 mood, anxiety, substance use, and stress- melatonin receptor agonist (ramelteon) and and trauma-related disorders.
    [Show full text]
  • Integration of Reward Signalling and Appetite Regulating Peptide Systems
    British Journal of DOI:10.1111/bph.13321 BJP www.brjpharmacol.org Pharmacology REVIEW Correspondence Amy C. Reichelt, PhD, School of Psychology, UNSWAustralia, NSW 2052, Australia. Integration of reward signalling E-mail: [email protected] --------------------------------------------------------- and appetite regulating peptide Received 3 June 2015 Revised systems in the control of 28 July 2015 Accepted food-cue responses 27 August 2015 A C Reichelt1,2, R F Westbrook1 and M J Morris2 1School of Psychology, UNSW Sydney, Sydney, UNSW, Australia, and 2School of Medical Sciences, UNSW Sydney, Sydney, UNSW, Australia Understanding the neurobiological substrates that encode learning about food-associated cues and how those signals are modulated is of great clinical importance especially in light of the worldwide obesity problem. Inappropriate or maladaptive responses to food-associated cues can promote over-consumption, leading to excessive energy intake and weight gain. Chronic exposure to foods rich in fat and sugar alters the reinforcing value of foods and weakens inhibitory neural control, triggering learned, but maladaptive, associations between environmental cues and food rewards. Thus, responses to food-associated cues can promote cravings and food-seeking by activating mesocorticolimbic dopamine neurocircuitry, and exert physiological effects including salivation. These responses may be analogous to the cravings experienced by abstaining drug addicts that can trigger relapse into drug self-administration. Preventing cue-triggered eating may therefore reduce the over-consumption seen in obesity and binge-eating disorder. In this review we discuss recent research examining how cues associated with palatable foods can promote reward-based feeding behaviours and the potential involvement of appetite-regulating peptides including leptin, ghrelin, orexin and melanin concentrating hormone.
    [Show full text]
  • Role of Catecholamine Pathways in Action of Orexin B Induced Open Field Activity by Nucleus Accumbens in Wistar Rats
    Pharmacogn J. 2018; 10(4):628-632 A Multifaceted Journal in the field of Natural Products and Pharmacognosy Original Article www.phcogj.com | www.journalonweb.com/pj | www.phcog.net Role of Catecholamine Pathways in Action of Orexin B Induced Open Field Activity by Nucleus Accumbens in Wistar Rats Rashmi Kaup Shiva1, Ganaraja Bolumbu2*, Santosh Mayannavar3, Dharnappa Poojari3 ABSTRACT Aims: To elucidate whether exploratory behaviour changes following Orexin B infusion in NAc is mediated through catecholamines in male Wistar rats. Methods: Inbred male Wistar rats (n= 24) were divided into three groups. Control, Treated 1 (Orexin B) and Treated 2 (Orexin B antagonist) groups. Using stereotaxic method, guide cannula was set in place bilaterally to reach Nucleus Accumbens. Orexin B and its antagonist, TCS-OX2-29 were infused in separate groups of overnight fasted rats. Following open field activity, catecholamines (Dopamine, Adrenaline, and Noradrenaline) were estimated in brain tissue homogenate by ELISA. Data were expressed as mean±SEM (ANOVA; Student-Newman Keuls test,).p<0.05 were considered as statistically significant. Results: Orexin B infusion significantly increased Rashmi Kaup Shiva1, noradrenaline levels in Nucleus accumbens when compared to controls. TCS-OX2-29 signifi- Ganaraja Bolambu2*, cantly decreased noradrenaline in Nucleus accumbens during open field exploration activity. 3 Adrenaline was not altered significantly during open field activity. Conclusion: These results SantoshMayannavar suggest that Orexin B, which plays a role in the regulation of motor and exploratory behaviour 1 when infused in NAc mediates these actions through noradrenergic neurotransmission in Department of Physiology, Centre for Nucleus Accumbens. Basic Sciences, Kasturba Medical Key words: Adrenaline, Dopamine, Nucleus Accumbens, Noradrenaline, Orexin B, TCS- College (A unit of Manipal Academy of Higher Education (MAHE), Manipal), OX2-29.
    [Show full text]